102 results about "Dosing Frequency" patented technology

Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.

A method of cancer treatment is provided that includes administering an effective amount of an endogenous ligand for the aryl hydrocarbon (Ah) receptor (AhR) named ITE or one of its structural analogs (the active ingredient) to a subject with cancer is disclosed. An effective dose and dosing frequency of the active ingredient are determined by measuring its blood levels of the subject after dosing. The active ingredient formulated with a carrier system is applied topically, enterally, or parenterally to the subject. An oral dose of water, in addition to normal water drinking, is administered to help alleviate feces hardening, a complication of ITE dosing. Subjects with cancers of skin, colon (or rectum), stomach, pancreas, kidney, bladder, soft tissue, and cervix, are preferably accepted for treatment or intervention.

The invention discloses a control method and a control method for treating sludge digestion liquid through sludge-fermentation-coupled denitrification, and belongs to the technical fields of high-ammonia-nitrogenous wastewater treatment and primary sludge biochemical treatment. The device is provided with a raw water tank, a sludge-fermentation-coupled denitrification reactor, a sedimentation tank and a sludge storage tank; and through oxide resume power (ORP) / pH sensors arranged in an aerobic reaction area and a fermentation-coupled denitrification reaction area, the aeration amount supply, the effluent backflow ratio and the dosing frequency and quality of primary sludge are optimally controlled. The invention is suitable for optimally controlling the treatment of the sludge digestion liquid by dosing the primary sludge serving as a denitrification carbon source, and can save carbon sources and improve denitrification efficiency. In addition, the control strategy has the advantages of simple operation and obvious effect.

A medication dispenser comprises slots that may be sized to accommodate medication containers of various sizes. Each slot has an associated barcode reader. A user inserts the pharmacy-provided pill or medication container into one slot. The barcode on the container is read. From the barcode the medication in the container is identified. The device contains a simple user interface that allows the user to enter the dosing frequency prescribed, how many pills or cc's are in the container, how many refills and a starting time. The dispenser alerts users to possible drug interactions with medications in other slots as well as alerts them to dosing times and other pertinent information.

The invention relates to a cyclosporine A micelle eye drop and a preparing method thereof. The cyclosporine A micelle eye drop comprises cyclosporine A used as a main drug, aseptic and isoosmotic adjusting agents, and is characterized by further comprising a copolymer of polythene caprolactam, polyvinyl acetate and polyethylene glycol used as drug auxiliary materials. The preparing method includes: preparing a cyclosporine A micelle through a solvent rotary evaporation film forming method; obtaining cyclosporine A micelle powder after filtering, freezing and drying the cyclosporine A micelle; and dispersing and dissolving the powder into a buffer solution to obtain the cyclosporine A micelle eye drop. According to the cyclosporine A micelle eye drop, the cyclosporine A has good solubility in a water solution, the micelle is small in particle diameter and uniform in distribution range and drug stability is good. The cyclosporine A micelle eye drop not only reduces drug irritation, but also improves drug absorption of a cornea, reduces drug concentration, prolongs drug action time, reduces dosing frequency, improves patient compliance, and has good economical efficiency.

The invention provides a pesticide film forming agent used for controlling diseases and insect pests of forest trees, and its preparation method. The pesticide film forming agent comprises 0.5-10% of an active component, 0.5-10% of a film forming aid, 5-15% of a solvent, 5-15% of an aid and 50-80% of water; and the active component is one of or a mixture comprising several of tebuconazole, difenoconazole, propiconazole and emamectin benzoate. The drug film forming agent has a good control effect on the diseases and insect pests of the forest trees, has a low price, is convenient to use, and has a good control effect on the dry rot diseases of hickory trees, the canker of various trees, stalk longhorn beetles and bark beetles, leaf aphids, red spider mites and the like especially; the drug film forming agent reduces the active component volatilization and loss possibility and changes the release performance, so the residual period is prolonged, the drug dose and the dosing frequency are reduced; and the drug film forming agent reduces the toxicity of highly toxic pesticides, reduces the acute toxicity of pesticides, reduces the drift of the pesticides, and mitigates the pollution to the environment and the hazard to crops.

The invention provides use and a preparation method of vaginal thermosensitive gel. The use is the use of the vaginal thermosensitive gel in the preparation of medicaments for treating vaginitis including bacterial vaginitis, mycotic vaginitis, mycoplasmal vaginitis, trichomonas vaginitis and senile vaginitis. The vaginal thermosensitive gel of the invention has a pH value in accordance with a vaginal environment, high patient tolerance and long in-vivo duration of more than 20 hours and therefore can reduce dosing frequency, improve patient compliance, strengthen the treatment effect of the medicaments and reduce toxic and side effects. In addition, the temperature of the gel is mild, so the gel has high liquidity before entering bodies and becomes solid after entering the bodies and the administration is convenient and sanitary.

The present invention discloses a method for preparing a Camellia nitidissima Chi lipid-lowering and hypoglycemic agent. Active components such as tea polysaccharides, tea polyphenols, and flavones are extracted from Camellia nitidissima Chi and purified, which are then mixed with pharmaceutical excipients such as hydroxypropyl methyl cellulose, polyvinylpyrrolidone, and triethyl citrate to prepare various pills, tablets, capsules, granules, etc. including sustained release agents and controlled release agents. Thereby, clinical or health care medicine effects of the Camellia nitidissima Chi lipid-lowering and hypoglycemic agent are improved, a dosing frequency is reduced, interference of impurities with the medicine effect is eliminated, relative bioavailability and safety of the active components of the Camellia nitidissima Chi lipid-lowering and hypoglycemic agent in a human body are enhanced, and compliance of a patient is improved.

The invention relates to a method for preparing abamectin microcapsules by complex coacervation, belonging to the technical field of preparation of microcapsules. The invention aims to provide a preparation method of novel abamectin microcapsules. The method comprises the following steps: taking sodium alginate as wall materials instead of combination of Arabic gums and gelatins and preparing the novel abamectin microcapsules by water bath solution, high-speed cutting and dispersing, acid regulating, cooling, reducing, solidifying and drying. The method has the advantages of low cost, small pollution, good film-forming property and so on; microencapsulation products have the embedding rate not less than 85%, the drug loading capacity not less than 75%, the lasting period increased by 3-8 times and the retention rate more than 70% after storing at room temperature for three months; the method effectively control the slow release effect of abamectins while improving the light stability of the abamectins and achieves the purposes of reducing the dosing frequency, the dosage and the cost and increasing a control effect.

Use of a growth hormone protein and polynucleotides encoding the same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing weight loss or body fat reduction, methods of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.

The invention relates to a temperature sensitive biogel preparation comprising, by mass, 20-30 parts of mesenchymal stem cell exosome, 20-28 parts poloxamer 407, 5-10 parts of poloxamer 188, 0.9-2.4 parts of polymer stabilizer for adjusting gelation temperature and drug release characteristics and 32-54 parts of water. The biocompatible degradable polymer is used as a drug-loading matrix of the mesenchymal stem cell exosome, and a polymer stabilizer is added to adjust the gelation temperature and the drug release characteristics, so that the loaded MSCs exosome can be released continuously toreduce the dosing frequency, prevent leakage of liquid medicine, improve the bioavailability and provide the safe effective preparation convenient to apply clinically for treatment of IUA.

The invention discloses a long-acting viscose dispersing type transdermal patch and a preparing process thereof and belongs to the medical technical field. The transdermal patch is mainly prepared from bulk pharmaceutical chemicals (such as non-steroid anti-inflammatory drug ibuprofen and salt form thereof, naproxen and salt form thereof, ketoprofen, indometacin and salt form thereof), a penetration enhancer (menthol, oleic acid, medium chain triglyceride, propylene glycol monolaurate, azone, propylene glycol and the like), a dispersing solvent (water, acetone, ethanol, carbinol, ethyl acetate and the like), a polyacrylate pressure-sensitive adhesive (crylic acid, butyl acrylate, crylic acid 2-ethylhexyl ester and the like), a backing layer and a release liner. The long-acting viscose dispersing type transdermal patch and the preparing process thereof have the advantages that drugs can be released from a matrix continuously for 12-48 h, the number of drug residues is low, transdermic absorption property is excellent, and dosing frequency and dosing amount can be reduced; skin irritation is avoided, and adhesion and compliance are high; main drugs and additives are stable in a viscose mechanism; preparing technology is simple, and pollution is avoided.

The invention discloses a venlafaxine hydrochloride sustained-release tablet preparation which comprises venlafaxine hydrochloride, framework material, diluent, lubricant, adhesive and coating material. The experiments demonstrate that the venlafaxine hydrochloride sustained-release tablet achieves better sustained-release effect, can reduce the dosing frequency and is convenient for the patients to use. The invention also provides a preparation method thereof.

The invention discloses adriamycin liposome temperature-sensitive gel and a preparation method thereof. The adriamycin liposome temperature-sensitive gel comprises the following components in parts by weight: 1-3 parts of adriamycin or adriamycin hydrochloride, 10-30 parts of soyabean lecithin, 2-8 parts of cholesterol, 5-20 parts of ammonium sulfate, 10-40 parts of 2-hydroxypropyl trimethyl ammonium chloride chitosan, 40-120 parts of sodium glycerophosphate and 500-1500 parts of menstruum. When the adriamycin liposome temperature-sensitive gel is applied to the tumor local injection, the anti-tumor effect of an adriamycin preparation is improved, the dosing frequency is reduced, and the systemic side effects are reduced; the nature of the temperature-sensitive gel is relatively stable and is unlikely to be affected by the environmental pH and the ionic strength.

The invention belongs to the technical field of skin care product composition preparation, and discloses a preparation method of an anti-wrinkle skin care product composition containing acetyl hexapeptide-8. The anti-wrinkle skin care product composition containing the acetyl hexapeptide-8 is prepared from materials in parts by weight: 0.5-6 parts of the acetyl hexapeptide-8, 0.1-0.5 part of sodium hyaluronate, 0.5-2 parts of palmitoyl tripeptide-5, 2 parts of butanediol, 0.5 part of [water, oligopeptide-1,dipotassium phosphate, sodium chloride and glycerinum], 90 parts of water and 0.1 part of arginine. According to the preparation method of the anti-wrinkle skin care product composition containing the acetyl hexapeptide-8, a percutaneous drug delivery penetrating mode of the acetyl hexapeptide-8 can be affected by individual metabolic rate and use dose frequency, and nursing is carried out according to static wrinkles and dynamic wrinkles so as to reach an anti-wrinkle personal care function. The preparation method of the anti-wrinkle skin care product composition containing the acetyl hexapeptide-8 can improve permeability of the acetyl hexapeptide-8 and repair of the static wrinkles, can be applied to addition of efficacy matters of facial mask essence, essence, emulsion and cream and milk for repairing skin in skin care products, and the product stability is protected.

The invention discloses a florfenicol suspension injection and a preparation procedure thereof, and relates to a medicine and a preparation procedure. The drug substance of the florfenicol suspension injection provided by the invention comprises the following components in part by weight: 40-100 parts of fat soluble florfenicol, 1.5-5 parts of suspending agent, 2-4 parts of wetting agent, 0.8-1.2 parts of citric acid, 0.3-0.5 parts of sodium citrate, 0.5-1 part of butylated hydroxytoluene and 5-40 parts of benzyl alcohol. The preparation procedure comprises the following steps: water for injection is used to dissolve the prescribed suspending agent into rubber paste to get solution 1; fat soluble florfenicol is evenly mixed with a wetting agent and water is added into the mixture of the fat soluble florfenicol and the wetting agent to form suspension to get solution 2; solution 1 is slowly added to solution 2 while stirring; citric acid, sodium citrate, butylated hydroxytoluene and benzyl alcohol is added, and then water is added to get 1000 ml of suspension; and the suspension is split and packed after stirring for 30-40 minutes to get florfenicol suspension injection. The florfenicol suspension injection has the advantages of broad antibacterial effect, strong antibacterial activity, low dosing frequency, little stress response and low price.

The invention discloses application of a conjugate of polyethylene glycol and local anesthetic to non-narcotic analgesia. The local anesthetic is made into a prodrug or a sustained release preparation, wherein high-molecular polymers such as polyethylene glycol in the prodrug are covalently bonded with local anesthetic, and auxiliary materials with a sustained release function in the sustained release preparation are covalently bonded with the local anesthetic. After application of the conjugate, anesthesia and analgesia effects are not achieved until release of free local anesthetic, and an analgesia effect is achieved after release of the free local anesthetic. Due to low release speed of the prodrug or the sustained release preparation of the local anesthetic, drug concentration can bestably and enduringly kept in an effective concentration range of non-narcotic analgesia, long-acting non-narcotic analgesia effects can be achieved while remarkable reduction of clinical untoward effects of the local anesthetic and reduction of dosing frequency are realized, drug effectiveness is improved, and a clinical application range of the local anesthetic is expanded.

The invention discloses a glucagon-like peptide-1 analogue sustained release microsphere as well as a preparation method and an application thereof. The sustained release microsphere mainly includes 1-10 parts by weight of the glucagon-like peptide-1 analogue and 90-99 parts by weight of a polylactic acid-glycollic acid copolymer and is 0.5-100 [mu]m in range of average particle size. The invention also discloses the preparation method and the application of the sustained release microsphere and also inspects appearance, particle size, in-vitro releasing and in-vivo pharmacodynamic experimentof the microsphere. The sustained release microsphere supporting GLP-1 analogue has uniform particle size and has significant treatment effect on diabetes, can effectively control blood glucose for 14days and has the effect as a slow-effect preparation. The sustained release microsphere greatly reduces dosing frequency and increases compliance of patients, and also can inhibit food intake. The preparation method has simple process and gentle conditions, and is low in influence on activities of polypeptides.

The invention belongs to the technical field of veterinary drug preparation, and relates to a compound doxycycline-hydrochloride florfenicol sustained-release microsphere suspension injection for veterinary use. The suspension injection is produced through a preparation technology combining an inclusion technology, a microcapsule technology and a high-pressure homogenization technology. The suspension injection comprises the following ingredients according to W / V: 10-30% of an inclusion material, 5-20% of doxycycline hydrochloride, 5-20% of florfenicol, 2.5-7.5% of a high-molecular capsule material, 0.2-1% of a suspending agent, 0.25-1% of an anti-oxidant, 0.05-0.2% of a metal chelator, 0.1-0.4% of an antiseptic, and the balance injection water. The active ingredients in the injection possess synergic antibacterial effects and obvious sustained release effect, clinic dosing frequency is reduced, the injection does not contain organic solvents, does not stimulate target animals, is small in toxic and side effects, and is capable of controlling respiratory diseases caused by streptococcus suis, actinobacillus pleuropneumoniae, pasteurella multocida, haemophilus parasuis, mycoplasma and the like.

The invention discloses a compound simvastatin niacin sustained release tablet and a preparation method thereof. The compound simvastatin niacin sustained release tablet consists of the following four components: (1) a tablet core containing niacin; (2) an isolation layer; (3) a simvastatin layer; and (4) a protective film-coat layer. In the compound preparation, the niacin serves as a sustained release component and the simvastatin serves as a quick release component, thus all components play a synergistic action in vivo to comprehensively adjust the components of blood fat so as to play the drug action to the utmost extent, reduce the toxic side effects of the medicaments, reduce the fluctuation of the blood concentration in vivo, and reduce the dosing frequency of a patient; and the compound simvastatin niacin sustained release tablet is applicable to treating hypercholesteremia and mixed dyslipidemia.

The invention discloses an oil-in-water type sotalol nanoemulsion antihypertensive drug, the raw materials and the mass percentages of each raw material are: 1%-18% of sotalol, 15%-40% of surfactant, Co-surfactant is 0-25%, the rest is distilled water, and the sum of the mass percentages of the above-mentioned raw materials is 100%. The nano-emulsion emulsion has small particles, uniform distribution, low viscosity and good fluidity. After the water-soluble drug sotalol is prepared into nanoemulsion form, the stability and drug efficacy of sotalol are increased, the antihypertensive effect is obviously increased, the half-life of the drug is prolonged, and the number of administrations is reduced.

The invention discloses a gynecological disease resisting gel for treating gynecological disease and a preparation method. The gynecological disease resisting gel comprises the following components in parts by weight: 225-275 parts of radix sophorae flavescentis, 225-275 parts of polygonum perfoliatum, 135-165 parts of amur corktree bark, 45-55 parts of fructus forsythiae, 27-33 parts of motherwort herb, 27-33 parts of red bean, 27-33 parts of folium artemisiae argyi, 27-33 parts of Chinese angelica, and 27-33 parts of combined spicebush root. The preparation method of the gynecological disease resisting gel is as follows: crushing 160 parts of the total amount of the radix sophorae flavescentis, 90 parts of the total amount of the amur corktree bark, 15 parts of the total amount of the fructus forsythiae and 15 parts of the total amount of the red bean into fine powder for later use; adding water into nine medicine materials such as the rest of radix sophorae flavescentis, polygonum perfoliatum and the like, decocting for two times with the first time for 2 hours and the second time for 1 hour; combining decocted liquid, filtering to obtain filtered liquid, concentrating the filtered liquid to thick paste with the relative density of 1.31-1.35 at the temperature of 60-80 DEG C, adding the fine powder, and mixing uniformly; taking a medium, adding water for swelling, and preparing into 0.1-0.5% glue solution; and adding 2.5-5 parts of medicinal thick paste into 2.5-5 parts of glue solution, adding water under stirring, preparing into 1-4 parts of 30% wetting agent solution, and stirring uniformly, thus obtaining the gynecological disease resisting gel. By utilizing the invention, the dosing frequency can be greatly reduced, the treatment cycle is short, and the efficiency is high.

The invention relates to a controlled release preparation containing 5-methyltetrahydrofolate. The controlled release preparation comprises a 5-methyltetrahydrofolate osmotic pump tablet core and a polymeric semi-permeable membrane coating layer. The semi-permeable membrane coating layer accounts for 2-15% of the weight of the tablet core, and the 5-methyltetrahydrofolate osmotic pump tablet corecan be a single-layer tablet or a double-layer tablet. By means of the preparation, 5-methyltetrahydrofolate can be slowly and stably released for a long time, the dosing frequency is reduced, and themedication compliance of a patient is improved.

Provided is a transdermal drug delivery system comprising cannabidiol, or a cannabidiol salt alone or in combinations thereof. Transdermal delivery can provide a drug plasma concentration at predetermined rate for a predetermined period of time with a simplified therapeutic regimen by decreasing dosing frequency for the treatment and / or prevention of pain and / or inflammation.

Disclosed is a method for preparing aceclofenac enteric microcapsules, comprising dissolving eudragit II, hydroxypropylmethylcellulose phthalate (HPMCP) or cellulose acetate phthalate in acetone to acquire a solution A; then adding aceclofenac powder into the solution A and fully dissolving the aceclofenac powder to obtain a solution B, and acquiring a primary emulsion by placing the solution B in a flask and stirring; adding span 80 into liquid paraffin and fully stirring; adding the primary emulsion into the well-stirred liquid paraffin, heating up to 75 DEG C gradually while stirring, and acquiring microcapsules by stirring continuously while preserving the temperature; and washing the microcapsules by using n-hexane three times after filtering and drying to acquire the finished microcapsules. According to the invention, the aceclofenac slow-release enteric microcapsules are prepared by using a property that decomposition of a capsule wall material is influenced by pH values. Through controlling the capsule wall material, the following effects can be achieved: drugs are sent directionally to the small intestine and released slowly to gentle the plasma concentration, prolong the action time, and improve the curative effect; the dosing frequency can be reduced and the plasma concentration is maintained in the body; and an adverse reaction in the gastrointestinal tract is reduced effectively and patient compliance is also improved effectively.

The invention provides an aceclofenac bi-layer osmotic pump controlled release tablet and a preparation method thereof, belongs to the technical field of medicinal preparation. The osmotic pump preparation comprises a tablet core containing aceclofenac and a semipermeable coating membrane which is coated outside the tablet core and provided with orifices, the tablet core comprises a drug layer containing aceclofenac and a boosting layer; wherein, the drug layer comprises the following components: 200mg of aceclofenac, 100mg-300mg of suspension, 10mg-50mg of osmotic stress active substance and0.5 mg-2mg of lubricant; the boosting layer comprises 50mg-150mg of sweller and 5mg-30mg of osmotic stress active substance; the semipermeable coating membrane comprises the following components: 10g-20g of semipermeable high polymer material dissolved in 500ml of acetone and 2g-5g of water soluble pore former dissolved in 20ml of distilled water and the weight of the coating membrane is 5%-10% of the tablet core weight; laser or a power drill is used to drill the orifices on the drug-containing side of the coating tablet. The invention is characterized of less dosing frequency, convenient taking way, long lasting and stable curative effect and can be used to cure pains and inflammations caused by osteoarthritis, rheumatoid arthritis, ankylosing spondylitis and the like.

The invention provides a trimetazidine hydrochloride bi-layer osmotic pump controlled release tablet and a preparation method thereof. The osmotic pump controlled release tablet is formed by a drug-containing layer, a booster layer and a coating film, wherein the drug-containing layer comprises the following components in percentage by weight: 10-50% of trimetazidine hydrochloride, 30-80% of suspension agent and the balance of other auxiliary materials; the booster layer comprises the following components in percentage by weight: 20-90% of swelling agent, 5-70% of osmotic active substance and 0.5-5% of lubricating agent; the semipermeable coating film comprises 10-20g of semipermeable high polymer material and 1-5g of water-soluble pore-forming agent every 100 tablets. The trimetazidine hydrochloride bi-layer osmotic pump controlled release tablet can realizes constant release of drug in the body of a patient without being affected by pH value of a medium environment, enzyme, gastrointestinal motility and food, and is capable of maintaining the stability of plasma concentration of drug, reducing toxic and side effects of drug, decreasing dosing frequency and improving compliance of the patient.

The invention relates to a low-toxicity nematode pesticide comprising the following components: 10-20 parts of cypermethrin, 5-8 parts of dibutyl citrate calcium naphthalene sulfonate, 2-7 parts of xylene, 5-20 parts of common threewingnut root, 10-25 parts of Indian quassawood extract liquid, 12-22 parts of aromatic hydrocarbon liquid, 5-10 parts of ferrous sulfate, 20-25 parts of kerosene, and 20-40 parts of water. The pesticide also comprises 2-10 parts of tetramethrin. The pesticide comprises 15-20 parts of the Indian quassawood extract liquid. The low-toxicity nematode pesticide provided by the invention is suitable for various vegetable, melon, and fruit crops. With the pesticide, dosing frequency can be reduced, yield can be increased, melon and fruit sweetness can be improved, and cost can be saved. The pesticide has good practical value.